1059 related articles for article (PubMed ID: 23933094)
21. Effects of some novel inhibitors of C17,20-lyase and 5alpha-reductase in vitro and in vivo and their potential role in the treatment of prostate cancer.
Nnane IP; Kato K; Liu Y; Lu Q; Wang X; Ling YZ; Brodie A
Cancer Res; 1998 Sep; 58(17):3826-32. PubMed ID: 9731491
[TBL] [Abstract][Full Text] [Related]
22. An overview on 5alpha-reductase inhibitors.
Aggarwal S; Thareja S; Verma A; Bhardwaj TR; Kumar M
Steroids; 2010 Feb; 75(2):109-53. PubMed ID: 19879888
[TBL] [Abstract][Full Text] [Related]
23. Aromatic esters of progesterone as 5alpha-reductase and prostate growth inhibitors.
Bratoeff E; Segura T; Recillas S; Carrizales E; Palacios A; Heuze I; Cabeza M
J Enzyme Inhib Med Chem; 2009 Jun; 24(3):655-62. PubMed ID: 18825535
[TBL] [Abstract][Full Text] [Related]
24. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.
Clark RV; Hermann DJ; Cunningham GR; Wilson TH; Morrill BB; Hobbs S
J Clin Endocrinol Metab; 2004 May; 89(5):2179-84. PubMed ID: 15126539
[TBL] [Abstract][Full Text] [Related]
25. Human type 3 3alpha-hydroxysteroid dehydrogenase (aldo-keto reductase 1C2) and androgen metabolism in prostate cells.
Rizner TL; Lin HK; Peehl DM; Steckelbroeck S; Bauman DR; Penning TM
Endocrinology; 2003 Jul; 144(7):2922-32. PubMed ID: 12810547
[TBL] [Abstract][Full Text] [Related]
26. In vivo and in vitro effect of novel 4,16-pregnadiene-6,20-dione derivatives, as 5alpha-reductase inhibitors.
Bratoeff E; Cabeza M; Pérez-Ornelas V; Recillas S; Heuze I
J Steroid Biochem Mol Biol; 2008 Sep; 111(3-5):275-81. PubMed ID: 18644453
[TBL] [Abstract][Full Text] [Related]
27. The direct inhibitory effect of dutasteride or finasteride on androgen receptor activity is cell line specific.
Chhipa RR; Halim D; Cheng J; Zhang HY; Mohler JL; Ip C; Wu Y
Prostate; 2013 Oct; 73(14):1483-94. PubMed ID: 23813737
[TBL] [Abstract][Full Text] [Related]
28. Partitioning of 5alpha-dihydrotestosterone and 5alpha-androstane-3alpha, 17beta-diol activated pathways for stimulating human prostate cancer LNCaP cell proliferation.
Nunlist EH; Dozmorov I; Tang Y; Cowan R; Centola M; Lin HK
J Steroid Biochem Mol Biol; 2004 Jul; 91(3):157-70. PubMed ID: 15276623
[TBL] [Abstract][Full Text] [Related]
29. Androgen metabolism in the prostate of the finasteride-treated, adult rat: a possible explanation for the differential action of testosterone and 5 alpha-dihydrotestosterone during development of the male urogenital tract.
George FW
Endocrinology; 1997 Mar; 138(3):871-7. PubMed ID: 9048585
[TBL] [Abstract][Full Text] [Related]
30. Prostate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through synthesis of testosterone and dihydrotestosterone from dehydroepiandrosterone.
Mizokami A; Koh E; Izumi K; Narimoto K; Takeda M; Honma S; Dai J; Keller ET; Namiki M
Endocr Relat Cancer; 2009 Dec; 16(4):1139-55. PubMed ID: 19608712
[TBL] [Abstract][Full Text] [Related]
31. 11β-hydroxyandrostenedione, the product of androstenedione metabolism in the adrenal, is metabolized in LNCaP cells by 5α-reductase yielding 11β-hydroxy-5α-androstanedione.
Swart AC; Schloms L; Storbeck KH; Bloem LM; Toit Td; Quanson JL; Rainey WE; Swart P
J Steroid Biochem Mol Biol; 2013 Nov; 138():132-42. PubMed ID: 23685396
[TBL] [Abstract][Full Text] [Related]
32. 5α-reductase type 3 enzyme in benign and malignant prostate.
Titus MA; Li Y; Kozyreva OG; Maher V; Godoy A; Smith GJ; Mohler JL
Prostate; 2014 Feb; 74(3):235-49. PubMed ID: 24150795
[TBL] [Abstract][Full Text] [Related]
33. Proliferative effect of androst-4-ene-3,17-dione and its metabolites in the androgen-sensitive LNCaP cell line.
Laplante Y; Poirier D
Steroids; 2008 Mar; 73(3):266-71. PubMed ID: 18082864
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of androgen synthesis in human testicular and prostatic microsomes and in male rats by novel steroidal compounds.
Nnane IP; Kato K; Liu Y; Long BJ; Lu Q; Wang X; Ling YZ; Brodie A
Endocrinology; 1999 Jun; 140(6):2891-7. PubMed ID: 10342882
[TBL] [Abstract][Full Text] [Related]
35. Increased androgen receptor and remodeling in the prostatic stroma after the inhibition of 5-alpha reductase and aromatase in gerbil ventral prostate.
Corradi LS; Góes RM; Vilamaior PS; Taboga SR
Microsc Res Tech; 2009 Dec; 72(12):939-50. PubMed ID: 19484778
[TBL] [Abstract][Full Text] [Related]
36. Effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer.
Stanczyk FZ; Azen CG; Pike MC
J Steroid Biochem Mol Biol; 2013 Nov; 138():10-6. PubMed ID: 23474436
[TBL] [Abstract][Full Text] [Related]
37. 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.
Rittmaster RS
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):389-402. PubMed ID: 18471794
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and activity of novel 16-dehydropregnenolone acetate derivatives as inhibitors of type 1 5α-reductase and on cancer cell line SK-LU-1.
Silva-Ortiz AV; Bratoeff E; Ramírez-Apan T; Heuze Y; Sánchez A; Soriano J; Cabeza M
Bioorg Med Chem; 2015 Dec; 23(24):7535-42. PubMed ID: 26631442
[TBL] [Abstract][Full Text] [Related]
39. Cynanchum wilfordii Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia by Regulating 5α-Reductase and Androgen Receptor Activities in a Rat Model.
Lee G; Shin J; Choi H; Jo A; Pan S; Bae D; Lee Y; Choi C
Nutrients; 2017 Sep; 9(10):. PubMed ID: 28953224
[TBL] [Abstract][Full Text] [Related]
40. Profiling adrenal 11β-hydroxyandrostenedione metabolites in prostate cancer cells, tissue and plasma: UPC
du Toit T; Bloem LM; Quanson JL; Ehlers R; Serafin AM; Swart AC
J Steroid Biochem Mol Biol; 2017 Feb; 166():54-67. PubMed ID: 27345701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]